Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dania Felipe-Ramirez

Pediatric Endocrinology New Orleans, LA Medical Doctor

NPI 1184814659 CMS profile 1137452

200 Henry Clay Ave, Children's Hospital Research Bldg, New Orleans, LA 70118

Open in the dashboard

General payments

$2,624

119 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$3,570 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Dania Felipe-Ramirez of New Orleans, LA is reported in the CMS Open Payments database as having received $2,624 across 119 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $3,570 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 67th percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $383 18
2024 General $480 17
2023 General $256 14
2022 General $252 15
2021 General $343 18
2020 General $315 14
2019 General $595 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dania Felipe-Ramirez
  • Pediatric Endocrinology median
  • Middle half of Pediatric Endocrinology
  • National median

In program year 2025, general payments to Dania Felipe-Ramirez were reported at $383. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.

Show as a table
Year Dania Felipe-Ramirez Pediatric Endocrinology median Middle half National median
2019 $595 $196 $68–$845 $163
2020 $315 $124 $37–$722 $114
2021 $343 $134 $35–$691 $132
2022 $252 $177 $47–$726 $149
2023 $256 $236 $75–$887 $160
2024 $480 $259 $91–$979 $164
2025 $383 $293 $106–$1,640 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $341 16 payments
  2. Alexion Pharmaceuticals, Inc. $270 9 payments
  3. AbbVie, Inc. $194 11 payments
  4. Ultragenyx Pharmaceutical Inc. $185 5 payments
  5. Beta Bionics, Inc. $180 4 payments
  6. Lilly USA, LLC $143 9 payments
  7. Pfizer Inc. $142 6 payments
  8. Ascendis Pharma, Inc. $135 7 payments
  9. Endo Pharmaceuticals Inc. $107 6 payments
  10. Tolmar, Inc. $90 4 payments
  11. Other $838 42 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,624 119 payments
Products named General payments · program years 2019–2025
  1. Strensiq $257 8 payments
  2. LUPRON DEPOT $175 10 payments
  3. iLet Bionic Pancreas Automated insulin delivery system $154 2 payments
  4. iLet Bionic Pancreas Automated insulin delivery system $154 2 payments
  5. iLet Bionic Pancreas Automated insulin delivery system $154 2 payments
  6. GENOTROPIN $142 6 payments
  7. SKYTROFA $135 7 payments
  8. Norditropin $133 6 payments
  9. Sogroya $116 5 payments
  10. NGENLA $115 5 payments
  11. Other $1,560 82 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

119 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Endocrinology in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record